Pharmaceutical

PRO-1107 by ProfoundBio Suzhou for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer).

Apr 21, 2024 - 00:00
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer).
Read the original article

Tags:

Previous Article

KAIST develops sodium battery capable of rapid charging in just a few seconds​

Next Article

PRO-1107 by ProfoundBio Suzhou for Fallopian Tube Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA advisers vote overwhelmingly against ALS treatment from BrainStorm

STAT+: FDA advisers vote overwhelmingly against ALS tre...

Sep 28, 2023

Ginkgo buys StrideBio’s AAV discovery and engineering platform assets

Ginkgo buys StrideBio’s AAV discovery and engineering p...

Apr 6, 2023

Inflationary pressure causes drop-off in contract manufacturing M&A

Inflationary pressure causes drop-off in contract manuf...

Jul 29, 2023